These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 36827874)
21. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. Madelon N; Heikkilä N; Sabater Royo I; Fontannaz P; Breville G; Lauper K; Goldstein R; Grifoni A; Sette A; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS JAMA Neurol; 2022 Apr; 79(4):399-404. PubMed ID: 35212717 [TBL] [Abstract][Full Text] [Related]
22. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis. Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006 [TBL] [Abstract][Full Text] [Related]
23. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption. Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE Front Immunol; 2023; 14():1219560. PubMed ID: 37575257 [TBL] [Abstract][Full Text] [Related]
24. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study. Alfonso-Dunn R; Lin J; Lei J; Liu J; Roche M; De Oliveira A; Raisingani A; Kumar A; Kirschner V; Feuer G; Malin M; Sadiq SA Front Immunol; 2023; 14():1194671. PubMed ID: 37449202 [TBL] [Abstract][Full Text] [Related]
25. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment. Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045 [TBL] [Abstract][Full Text] [Related]
26. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis. Smith JB; Gonzales EG; Li BH; Langer-Gould A JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740 [TBL] [Abstract][Full Text] [Related]
27. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226 [TBL] [Abstract][Full Text] [Related]
29. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy. Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V Front Immunol; 2023; 14():1296148. PubMed ID: 38259440 [TBL] [Abstract][Full Text] [Related]
30. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. Satyanarayan S; Safi N; Sorets T; Filomena S; Zhang Y; Klineova S; Fabian M; Horng S; Tankou S; Miller A; Krieger S; Lublin F; Sumowski J; Katz Sand I Mult Scler Relat Disord; 2022 Jun; 62():103737. PubMed ID: 35533419 [TBL] [Abstract][Full Text] [Related]
31. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A; EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483 [TBL] [Abstract][Full Text] [Related]
32. The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type. Jakubecz C; Zhang XS; Woodson S; Serra A; Abboud H Mult Scler Relat Disord; 2022 May; 61():103785. PubMed ID: 35381535 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy. Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884 [TBL] [Abstract][Full Text] [Related]
34. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis. Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G Front Immunol; 2022; 13():960001. PubMed ID: 36311767 [TBL] [Abstract][Full Text] [Related]
35. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Tallantyre EC; Scurr MJ; Vickaryous N; Richards A; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Rios F; Schmierer K; Willis M; Godkin A; Dobson R Mult Scler Relat Disord; 2022 Aug; 64():103937. PubMed ID: 35700625 [TBL] [Abstract][Full Text] [Related]
36. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F Front Immunol; 2021; 12():781843. PubMed ID: 34956211 [TBL] [Abstract][Full Text] [Related]